A Phase 2 Multi-center Open-label Trial of Nab-Sirolimus in Combination With Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer

Inclusion Criteria: 1. Patients must have clinically confirmed advanced or recurrent endometrioid endometrial carcinoma. Histologic documentation of the recurrence is suggested but not required. 2. All patients must have 1 or more measurable target lesion at baseline by computed tomography (CT; or magnetic resonance imaging \[MRI\] if CT scans are contraindicated) as defined by RECIST version 1.1. 3. Patients must have EEC that is metastatic or locally advanced where surgical resection is not an option or likely to result in severe morbidity. 4. Prior treatment history: 1. Adjuvant settin…